Reactivos e instrumentos para inmunología, biología celular y biología molecular.

Arachidonic acid [506-32-1]

Imprimir

Referencia HY-109590-10mg

embalaje : 10mg

Marca : MedChemExpress

Solicitar más información

Descripciòn

Arachidonic acid (Immunocytophyt) is a polyunsaturated omega-6 fatty acid and a major constituent of biomembranes. Arachidonic acid also acts as the substrate for various lipid mediators, such as prostaglandins (PGs). Arachidonic acid improves cognitive response and cardiovascular function^[1].

IC₅₀ & Target

Human Endogenous Metabolite

Cellular Effect

Cell Line	Type	Value	Description	References
MDA-MB-468	EC₅₀	> 100 μM Compound: AA	Proapoptotic activity in human MDA-MB-468 cells assessed as activation of caspase-3 by luminometry Proapoptotic activity in human MDA-MB-468 cells assessed as activation of caspase-3 by luminometry	[PMID: 22822908]
MDA-MB-468	IC₅₀	> 100 μM Compound: AA	Antiproliferative activity against human MDA-MB-468 cells after 48 hrs by MTT assay Antiproliferative activity against human MDA-MB-468 cells after 48 hrs by MTT assay	[PMID: 22822908]
RBL-2H3	IC₅₀	> 50 μM Compound: 5	Antiallergic activity in rat RBL2H3 cells assessed as inhibition of DNP-HSA-mediated degranulation by measuring decrease in beta-hexosaminidase activity preincubated for 30 mins followed by DNP-HSA stimulation and measured after 30 mins by 4-nitrophenyl 2-acetamido-2-deoxy-beta-D-glucopyranoside substrate based assay Antiallergic activity in rat RBL2H3 cells assessed as inhibition of DNP-HSA-mediated degranulation by measuring decrease in beta-hexosaminidase activity preincubated for 30 mins followed by DNP-HSA stimulation and measured after 30 mins by 4-nitrophenyl 2-acetamido-2-deoxy-beta-D-glucopyranoside substrate based assay	[PMID: 31618024]
THP-1	IC₅₀	180 nM Compound: AA-861	Concentration required to inhibit production of PGE-2 from THP-1 cells stimulated with A-23187 Concentration required to inhibit production of PGE-2 from THP-1 cells stimulated with A-23187	[PMID: 11229777]
THP-1	IC₅₀	4.7 nM Compound: AA-861	Concentration required to inhibit production of LTC4 from THP-1 cells stimulated with A-23187 Concentration required to inhibit production of LTC4 from THP-1 cells stimulated with A-23187	[PMID: 11229777]
THP-1	IC₅₀	40000 nM Compound: AA-861	Concentration required to inhibit production of arachidonic acid from THP-1 cells stimulated with A-23187 Concentration required to inhibit production of arachidonic acid from THP-1 cells stimulated with A-23187	[PMID: 11229777]
Ventricular myocyte	IC₅₀	5.8 μM Compound: Arachidonic acid	Inhibition of L-type calcium channel measured using whole-cell patch clamp in rat ventricular myocytes Inhibition of L-type calcium channel measured using whole-cell patch clamp in rat ventricular myocytes	[PMID: 22761000]
Ventricular myocyte	IC₅₀	8.5 μM Compound: Arachidonic acid	Inhibition of L-type calcium channel measured using whole-cell patch clamp in rat ventricular myocytes Inhibition of L-type calcium channel measured using whole-cell patch clamp in rat ventricular myocytes	[PMID: 22761000]

In Vitro

Arachidonic acid (0-100 µM, 24-72 h) decreases the viability of HL-60 cells in time- and dose-dependent manner^[3].
Arachidonic acid (0-100 µM, 6-24 h) reduces the G0-G1, S and G2-M DNA with increasing concentration and exposure time in HL-60 cells^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Note:
Please do not refer to only one article to determine the experimental conditions. It is recommended to determine the optimal experimental conditions (animal strain, age, dosage, frequency and cycle, detection time and indicators, etc.) through preliminary experiments before the formal experiment.

Arachidonic acid can be used to induce paw edema models^[2].

Induction of Paw Edema Model^[2]

Background

Principle: Injecting arachidonic acid into the hind paws of rats can induce rapid and sustained inflammatory responses.

Specific Modeling Methods

Rat: Lewis • male •
Administration: 0.5% • s.c. • single dose

Note

A single subcutaneous injection of 0.10 mL of arachidonic acid (dissolved in 0.2 M carbonate buffer with a pH value of 8.43-8.56) was administered into the right hind paw of male Lewis rats weighing 144-241 grams.

Modeling Indicators

Appearance Monitoring: Significant edema became apparent within 5 minutes, and the reaction reached its peak at 1 hour after injection.

Opposite Product(s): phenidone (HY-W010144); SK&F86002 (HY-12511)

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Male Lew rats (4-week-old) induced arthritis^[1]
Dosage:	0.07%, 0.15% or 0.32% in diet (w/w)
Administration:	4 weeks
Result:	The Arachidonic acid content of phospholipids in the paw was significantly elevated in a dose-dependent manner.

Peso molecular

304.47

Fòrmula

C₂₀H₃₂O₂

No. CAS

506-32-1

Appearance

Liquid (Density: 0.922 g/cm³)

Color

Colorless to light yellow

SMILES

CCCCC/C=C\C/C=C\C/C=C\C/C=C\CCCC(O)=O

Structure Classification

Ketones, Aldehydes, Acids

Initial Source

Animals

mammalian cell

Envío

Shipping with dry ice.

Almacenamiento

-80°C, protect from light, stored under nitrogen

Solvente y solubilidad

In Vitro:

Ethanol : 100 mg/mL (328.44 mM; Need ultrasonic)

DMSO : 100 mg/mL (328.44 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	3.2844 mL	16.4220 mL	32.8440 mL
5 mM	0.6569 mL	3.2844 mL	6.5688 mL
10 mM	0.3284 mL	1.6422 mL	3.2844 mL

View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months (protect from light, stored under nitrogen). When stored at -80°C, please use it within 6 months.

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: 2.5 mg/mL (8.21 mM); Suspended solution; Need ultrasonic

This protocol yields a suspended solution of 2.5 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (8.21 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil
Solubility: ≥ 2.5 mg/mL (8.21 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

Pureza y Documentación

Purity: 99.75%

Ficha de datos (274 KB) SDS (393 KB)

COA (237 KB) RP-HPLC (215 KB)

Instrucciones de manejo (2659 KB)

Referencias

[1]. Tateishi N, et al. Dietary supplementation with arachidonic acid increases arachidonic acid content in paw, but does not affect arthritis severity or prostaglandin E2 content in rat adjuvant-induced arthritis model. Lipids Health Dis. 2015 Jan 16;14:3. [Content Brief]

[2]. DiMartino MJ, et al. The pharmacology of arachidonic acid-induced rat paw edema. Agents Actions. 1987 Aug;21(3-4):303-5. [Content Brief]

[3]. Pompeia C, et al. Arachidonic acid cytotoxicity in leukocytes: implications of oxidative stress and eicosanoid synthesis. Biol Cell. 2002 Sep;94(4-5):251-65. [Content Brief]

Usted podría estar interesado también en los siguientes productos:

Referencia

Descripción

Cond.

Precio Sin IVA

228-11059-2

Lysostaphin Recombinant

5mg

228-11059-3

Lysostaphin Recombinant

10mg

Arachidonic acid [506-32-1]

Referencia HY-109590-10mg

Marca : MedChemExpress

Arachidonic acid Related Antibodies

Usted podría estar interesado también en los siguientes productos: